These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23134386)

  • 41. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
    Gonçalves A; Trédan O; Villanueva C; Dumontet C
    Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?
    Sendur MA; Aksoy S; Ozdemir Y; Zengin N; Altundag K
    J BUON; 2013; 18(3):801. PubMed ID: 24065505
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunoconjugates in the treatment of breast cancer.
    Tripathy D
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):469-72. PubMed ID: 25322329
    [No Abstract]   [Full Text] [Related]  

  • 44. Emerging strategies for the dual inhibition of HER2-positive breast cancer.
    Konecny GE
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):55-65. PubMed ID: 23241641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interest in "smart bombs" explodes.
    Cancer Discov; 2012 Oct; 2(10):864. PubMed ID: 23071018
    [No Abstract]   [Full Text] [Related]  

  • 46. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [New targeted therapies in breast cancer].
    Coussy F; Teixeira L; Giacchetti S; Cuvier C; Hocini H; Espié M
    Gynecol Obstet Fertil; 2014 Nov; 42(11):787-94. PubMed ID: 25442825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report.
    Miranda Romero P; Marín Gil R
    Farm Hosp; 2015 May; 39(3):171-5. PubMed ID: 26005893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance to human epidermal growth factor receptor type 2-targeted therapies.
    Thery JC; Spano JP; Azria D; Raymond E; Penault Llorca F
    Eur J Cancer; 2014 Mar; 50(5):892-901. PubMed ID: 24462377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review.
    Kalsi R; Feigenberg S; Kwok Y; Tkaczuk K; Mehta M; Chumsri S
    Clin Breast Cancer; 2015 Apr; 15(2):e163-6. PubMed ID: 25454740
    [No Abstract]   [Full Text] [Related]  

  • 53. [Monoclonal antibody therapy in breast cancer].
    Dank M; Tõkés T
    Magy Onkol; 2013 Sep; 57(3):157-65. PubMed ID: 24107821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.
    Shen K; Ma X; Zhu C; Wu X; Jia H
    Sci Rep; 2016 Mar; 6():23262. PubMed ID: 26979925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
    Bourdeanu L; Luu T
    Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
    Drachman JG; Senter PD
    Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?
    Theriault RL
    Oncologist; 2012; 17(2):157-9. PubMed ID: 22302226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.